Resectable hepatocellular carcinoma with high risk of recurrence
Clinical trials for Resectable hepatocellular carcinoma with high risk of recurrence explained in plain language.
Never miss a new study
Get alerted when new Resectable hepatocellular carcinoma with high risk of recurrence trials appear
Sign up with your email to follow new studies for Resectable hepatocellular carcinoma with high risk of recurrence, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo before liver surgery aims to stop cancer return
Disease control Recruiting nowThis phase 2 trial tests whether combining a liver-directed procedure (TACE) with two drugs—atezolizumab (immunotherapy) and bevacizumab (anti-angiogenic)—given before surgery can improve outcomes for patients with liver cancer at high risk of recurrence. About 30 adults with res…
Matched conditions: RESECTABLE HEPATOCELLULAR CARCINOMA WITH HIGH RISK OF RECURRENCE
Phase 2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Can immunotherapy given around liver cancer surgery stop the disease from coming back?
Prevention Recruiting nowResearchers are testing whether a combination immunotherapy called iparomlimab and tuvonralimab can prevent liver cancer from returning after surgery in patients whose tumors are at high risk of coming back. Participants receive one dose of the immunotherapy before surgery to rem…
Matched conditions: RESECTABLE HEPATOCELLULAR CARCINOMA WITH HIGH RISK OF RECURRENCE
Phase 2 • Sponsor: Tongji Hospital • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC